Leicestershire Health Community
Medicines Formulary
 
back
3 Respiratory system
03-04-02 Allergen Immunotherapy

Grass pollen extract sublingual Grazax®
Restricted
Restricted to initiation by specialist allergist / respiratory clinicians in line with criteria below.
Patients should be assessed at the end of each season to ensure adequate response before continuation
Link  Assessing Patient Suitability for Immunotherapy With Grazax
Link  SCA: Grazax
 

Restricted Drug Amber SCA View adult BNF  View SPC online
Mepolizumab Nucala®
Restricted

Asthma. For use by specialist respiratory clinician in line with NICE TA 431 to treat severe refractory eosinophilic asthma only.

Date of entry of decision to Formulary: March 2017

Link  NICE TA 431: Mepolizumab for treating severe refractory eosinophilic asthma
 

Restricted Drug Red View adult BNF  HCD
Reslizumab Cinqaero®
Restricted
For use in line with NICE TA 479 for the treatment of severe eosinophilic asthma only.

Date of entry of decision to Formulary: January 2018
Link  NICE TA 479: Reslizumab for treating severe eosinophilic asthma
 

Restricted Drug Red View adult BNF  View SPC online  HCD
Grass pollen extract subcutaneous  Pollinex®
Restricted
Restricted to initiation by specialist allergist / respiratory clinicians in line with criteria below
Link  Assessing Patient Suitability for Immunotherapy With Grazax
 

Restricted Drug Red View adult BNF  View SPC online  View childrens BNF